KRAS and neoplasm: Pulse can also be performed with peptides from multiple tumor antigens, as was performed in a Phase I clinical study by Carbone et al. Patients with various cancers, including pancreatic cancer, immunized with p53 and K-ras peptide-pulsed PBMCs, saw increased survival [142].